361 related articles for article (PubMed ID: 22102982)
21. Iron chelation and neuroprotection in neurodegenerative diseases.
Li X; Jankovic J; Le W
J Neural Transm (Vienna); 2011 Mar; 118(3):473-7. PubMed ID: 21161300
[TBL] [Abstract][Full Text] [Related]
22. Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
Devos D; Cabantchik ZI; Moreau C; Danel V; Mahoney-Sanchez L; Bouchaoui H; Gouel F; Rolland AS; Duce JA; Devedjian JC;
J Neural Transm (Vienna); 2020 Feb; 127(2):189-203. PubMed ID: 31912279
[TBL] [Abstract][Full Text] [Related]
23. Neuropeptides: Roles and Activities as Metal Chelators in Neurodegenerative Diseases.
Ben-Shushan S; Miller Y
J Phys Chem B; 2021 Mar; 125(11):2796-2811. PubMed ID: 33570949
[TBL] [Abstract][Full Text] [Related]
24. Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases.
Chang CP; Wu KC; Lin CY; Chern Y
J Biomed Sci; 2021 Oct; 28(1):70. PubMed ID: 34635103
[TBL] [Abstract][Full Text] [Related]
25. Benefits of curcumin in brain disorders.
Bhat A; Mahalakshmi AM; Ray B; Tuladhar S; Hediyal TA; Manthiannem E; Padamati J; Chandra R; Chidambaram SB; Sakharkar MK
Biofactors; 2019 Sep; 45(5):666-689. PubMed ID: 31185140
[TBL] [Abstract][Full Text] [Related]
26. Circadian rhythm alterations affecting the pathology of neurodegenerative diseases.
Canever JB; Queiroz LY; Soares ES; de Avelar NCP; Cimarosti HI
J Neurochem; 2023 Jun; ():. PubMed ID: 37358003
[TBL] [Abstract][Full Text] [Related]
27. Dissecting the Relationship Between Neuropsychiatric and Neurodegenerative Disorders.
Gupta R; Advani D; Yadav D; Ambasta RK; Kumar P
Mol Neurobiol; 2023 Nov; 60(11):6476-6529. PubMed ID: 37458987
[TBL] [Abstract][Full Text] [Related]
28. Roles and therapeutic potential of metallothioneins in neurodegenerative diseases.
Hozumi I
Curr Pharm Biotechnol; 2013; 14(4):408-13. PubMed ID: 23590138
[TBL] [Abstract][Full Text] [Related]
29. Aluminum in Neurological and Neurodegenerative Disease.
McLachlan DRC; Bergeron C; Alexandrov PN; Walsh WJ; Pogue AI; Percy ME; Kruck TPA; Fang Z; Sharfman NM; Jaber V; Zhao Y; Li W; Lukiw WJ
Mol Neurobiol; 2019 Feb; 56(2):1531-1538. PubMed ID: 30706368
[TBL] [Abstract][Full Text] [Related]
30. Copper dyshomoeostasis in Parkinson's disease: implications for pathogenesis and indications for novel therapeutics.
Davies KM; Mercer JF; Chen N; Double KL
Clin Sci (Lond); 2016 Apr; 130(8):565-74. PubMed ID: 26957644
[TBL] [Abstract][Full Text] [Related]
31. VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases.
Quinn JP; Kandigian SE; Trombetta BA; Arnold SE; Carlyle BC
Brain Commun; 2021; 3(4):fcab261. PubMed ID: 34778762
[TBL] [Abstract][Full Text] [Related]
32. The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer's Disease, Amyotrophic Lateral Sclerosis and Aging.
Kupershmidt L; Youdim MBH
Cells; 2023 Feb; 12(5):. PubMed ID: 36899898
[TBL] [Abstract][Full Text] [Related]
33. Imbalance of Essential Metals in Traumatic Brain Injury and Its Possible Link with Disorders of Consciousness.
Squitti R; Reale G; Tondolo V; Crescenti D; Bellini S; Moci M; Caliandro P; Padua L; Rongioletti M
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047843
[TBL] [Abstract][Full Text] [Related]
34. Systematic Review: Quantitative Susceptibility Mapping (QSM) of Brain Iron Profile in Neurodegenerative Diseases.
Ravanfar P; Loi SM; Syeda WT; Van Rheenen TE; Bush AI; Desmond P; Cropley VL; Lane DJR; Opazo CM; Moffat BA; Velakoulis D; Pantelis C
Front Neurosci; 2021; 15():618435. PubMed ID: 33679303
[TBL] [Abstract][Full Text] [Related]
35. The Zinc Ionophore Clioquinol Reduces Parkinson's Disease Patient-Derived Brain Extracts-Induced Neurodegeneration.
Teil M; Doudnikoff E; Thiolat ML; Bohic S; Bezard E; Dehay B
Mol Neurobiol; 2022 Oct; 59(10):6245-6259. PubMed ID: 35915387
[TBL] [Abstract][Full Text] [Related]
36. Copper homeostasis and the ubiquitin proteasome system.
Zhang B; Burke R
Metallomics; 2023 Mar; 15(3):. PubMed ID: 36822629
[TBL] [Abstract][Full Text] [Related]
37. Relationship of Sleep Disorder with Neurodegenerative and Psychiatric Diseases: An Updated Review.
Xiao X; Rui Y; Jin Y; Chen M
Neurochem Res; 2024 Mar; 49(3):568-582. PubMed ID: 38108952
[TBL] [Abstract][Full Text] [Related]
38. Nitric oxide and cellular stress response in brain aging and neurodegenerative disorders: the role of vitagenes.
Calabrese V; Boyd-Kimball D; Scapagnini G; Butterfield DA
In Vivo; 2004; 18(3):245-67. PubMed ID: 15341181
[TBL] [Abstract][Full Text] [Related]
39. Wilson's disease and other neurological copper disorders.
Bandmann O; Weiss KH; Kaler SG
Lancet Neurol; 2015 Jan; 14(1):103-13. PubMed ID: 25496901
[TBL] [Abstract][Full Text] [Related]
40. A Review on Chitosan in Drug Delivery for Treatment of Neurological and Psychiatric Disorders.
Shayganfard M
Curr Pharm Biotechnol; 2022; 23(4):538-551. PubMed ID: 34161209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
